Cardiff Oncology Inc reports results for the quarter ended December 31 - Earnings Summary

Cardiff Oncology

28/02/2025 24:58

Cardiff Oncology Inc CRDF.OQ reported a quarterly adjusted loss of 22 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -21 cents.  The mean expectation of six analysts for the quarter was for a loss of 24 cents per share. Wall Street expected results to range from -29 cents to -20 cents per share.

Revenue fell 3.2% to $151.00 thousand from a year ago; analysts expected $94.17 thousand.

Cardiff Oncology Inc's reported EPS for the quarter was a loss of 22 cents​.

The company reported a quarterly loss of $11.79 million.

Cardiff Oncology Inc shares had risen by 2.8% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 1.8% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Cardiff Oncology Inc is $11.50

This summary was machine generated from LSEG data February 28 at 12:58 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.24
-0.22
Beat
Sep. 30 2024
-0.27
-0.25
Beat
Jun. 30 2024
-0.25
-0.26
Missed
Mar. 31 2024
-0.25
-0.22
Beat